AbTis
Biotechnology company developing site-selective antibody conjugation linker technology for bioconjugates. The platform enables lysine site-specific conjugation without antibody re-engineering, control over drug-to-antibody ratio (DAR), dual-payload configurations, and tunable pharmacokinetics. The company offers platform and product licensing, fee-for-service ADC development and research-scale production, and collaborates with global CDMO partners. Acquired by Dong-A ST in 2023. Headquarters in Yongin-si, Gyeonggi-do, Republic of Korea.
Industries
Nr. of Employees
small (1-50)
AbTis
21, Geumhwa-ro 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea
Patents
Site-specific antibody conjugation and antibody-drug conjugate as specific embodiment thereof
US-11896675-B2
View Details
Site-specific antibody conjugation and antibody-drug conjugate as specific embodiment thereof
US-11896675-B2
View DetailsProducts
Bioconjugate pipeline (ADC, antibody-oligonucleotide, degrader-antibody, radionuclide, immune-stimulating conjugates)
Portfolio of bioconjugate therapeutic candidates and research assets using site-selective conjugation across multiple modalities for preclinical to IND-enabling development.
Clinical-stage ADC candidate targeting Claudin18.2
Clinical-stage ADC candidate directed to Claudin18.2 for gastrointestinal cancers; listed as a pipeline asset progressing to clinical development.
Bioconjugate pipeline (ADC, antibody-oligonucleotide, degrader-antibody, radionuclide, immune-stimulating conjugates)
Portfolio of bioconjugate therapeutic candidates and research assets using site-selective conjugation across multiple modalities for preclinical to IND-enabling development.
Clinical-stage ADC candidate targeting Claudin18.2
Clinical-stage ADC candidate directed to Claudin18.2 for gastrointestinal cancers; listed as a pipeline asset progressing to clinical development.
Services
Conjugation of client antibodies and payloads using the site-selective linker workflow under a fee-for-service engagement.
Non-GMP in-house production of milligram-to-gram quantities of conjugates for preclinical and early development studies.
Licensing of platform technology or specific candidates and collaborative co-development arrangements beginning with platform feasibility assessments.
Assistance for transfer from research-scale production to GMP manufacturing through partnerships with global CDMO/CRDMO organizations.
Conjugation of client antibodies and payloads using the site-selective linker workflow under a fee-for-service engagement.
Non-GMP in-house production of milligram-to-gram quantities of conjugates for preclinical and early development studies.
Licensing of platform technology or specific candidates and collaborative co-development arrangements beginning with platform feasibility assessments.
Assistance for transfer from research-scale production to GMP manufacturing through partnerships with global CDMO/CRDMO organizations.
Expertise Areas
- Antibody-drug conjugate development
- Bioconjugation and linker chemistry
- Platform-enabled bioconjugate modalities (antibody-oligonucleotide, degrader-antibody, radionuclide, immune-stimulating conjugates)
- Preclinical pharmacology and xenograft efficacy testing
Key Technologies
- Site-selective lysine conjugation
- Hydrophilic cleavable linker chemistry
- Drug-to-antibody ratio (DAR) control
- Dual-payload conjugation
News & Updates
Memorandum of understanding to integrate site-selective conjugation technology with CDMO capabilities for ADC R&D and manufacturing collaboration.
Business agreement to combine site-selective linker technology with a CMC development platform to accelerate ADC development and CMC timelines.
Published preclinical letter reporting a site-selective ADC using a platform linker with significant tumor growth inhibition in NSCLC xenograft models and a favorable pharmacokinetic profile.
Memorandum of understanding to integrate site-selective conjugation technology with CDMO capabilities for ADC R&D and manufacturing collaboration.
Business agreement to combine site-selective linker technology with a CMC development platform to accelerate ADC development and CMC timelines.
Published preclinical letter reporting a site-selective ADC using a platform linker with significant tumor growth inhibition in NSCLC xenograft models and a favorable pharmacokinetic profile.